A Glimpse Into The Expert Outlook On Steris Through 5 Analysts

SterisSTEhas been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings03200Last 30D010001M Ago000002M Ago012003M Ago01000Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $265.8, along with a high estimate of $280.00 and a low estimate of $250.00. Witnessing a positive shift, the current average has risen by 4.75% from the previous average price target of $253.75.Diving into Analyst Ratings: An In-Depth ExplorationThe perception of Steris by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.AnalystAnalyst FirmAction TakenRatingCurrent Price TargetPrior Price TargetPatrick WoodMorgan StanleyRaisesOverweight$276.00$260.00David WindleyJefferiesAnnouncesHold$263.00-Patrick WoodMorgan StanleyRaisesEqual-Weight$260.00$240.00David TurkalyJMP SecuritiesRaisesMarket Outperform$280.00$265.00Steven EtochStephens & Co.MaintainsOverweight$250.00$250.00Key Insights:Action Taken:Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Steris. This information offers a snapshot of how analysts perceive the current state of the company.Rating:Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Steris compared to the broader market.Price Targets:Gaining insights, analysts provide estimates for the future value of Steris's stock. This comparison reveals trends in analysts' expectations over time.Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Steris's market position. Stay informed and make well-informed decisions with our Ratings Table.Stay up to date on Steris analyst ratings.Get to Know Steris BetterSteris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.Understanding the Numbers: Steris's FinancesMarket Capitalization Analysis:Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.Revenue Growth:Steris displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately4.31%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.Net Margin:Steris's net margin is impressive, surpassing industry averages. With a net margin of9.84%,the company demonstrates strong profitability and effective cost management.Return on Equity (ROE):Steris's ROE stands out, surpassing industry averages. With an impressive ROE of2.24%, the company demonstrates effective use of equity capital and strong financial performance.Return on Assets (ROA):Steris's ROA excels beyond industry benchmarks, reaching1.45%. This signifies efficient management of assets and strong financial health.Debt Management:Steris's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of0.33.How Are Analyst Ratings Determined?Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.Breaking: Wall Street's Next Big MoverBenzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold.Click here for urgent details.This article was generated by Benzinga's automated content engine and reviewed by an editor.STESteris PLC$228.901.38%Stock Score Locked: Edge Members OnlyBenzinga Rankings give you vital metrics on any stock – anytime.Unlock RankingsEdge RankingsMomentum54.58Growth99.49Quality74.24Value12.51Price TrendShortMediumLongOverviewMarket News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. . .EarningsAnalyst RatingsOptionsDividendsIPOsdate▲▼ticker▲▼name▲▼Price Target▲▼Upside/Downside▲▼Recommendation▲▼Firm▲▼Click to see moreAnalyst RatingsupdatesAnalyst CalendarJoin Benzinga Edge and unlock all the major upgrades, downgrades, and changes to the market's most accurate analysts.Click to JoinPosted In:Analyst RatingsBZI-AAR